Guile SD, Bantick JR, Cheshire DR, Cooper ME, Davis AM, Donald DK, Evans R, Eyssade C, Ferguson DD, Hill S, Hutchinson R, Ingall AH, Kingston LP, Martin I, Martin BP, Mohammed RT, Murray C, Perry MWD, Reynolds RH, Thorne PV, Wilkinson DJ, Withnall J. Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.
Bioorg Med Chem Lett 2006;
16:2260-5. [PMID:
16455256 DOI:
10.1016/j.bmcl.2006.01.024]
[Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2005] [Revised: 01/05/2006] [Accepted: 01/06/2006] [Indexed: 11/24/2022]
Abstract
A novel series of potent blockers of the monocarboxylate transporter, MCT1, is disclosed. From very potent but lipophilic lead compounds, systematic changes to all parts of the molecule, targeting reduction in log D, afforded compounds with significantly improved overall properties. These compounds show potent immunomodulatory activity.
Collapse